Product Description
Product Name: Lopimune Tablets
Composition: Lopinavir 200 mg + Ritonavir 50 mg
Form: Oral Tablet
Category: Antiretroviral (Protease Inhibitor Combination)
Indication: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Lopimune Tablets is a fixed-dose combination of Lopinavir and Ritonavir, indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. This protease inhibitor-based regimen helps suppress viral replication, enhance immune function, and delay the progression of HIV-related illness.
Mechanism of Action:
Lopinavir inhibits the HIV-1 protease enzyme, preventing the cleavage of viral polyproteins, resulting in the production of immature, non-infectious viral particles.
Ritonavir acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A4 (CYP3A4), increasing the plasma concentration and effectiveness of Lopinavir.
Key Benefits:
Proven efficacy in reducing HIV viral load and increasing CD4 cell counts
Co-formulated for convenient dosing and improved adherence
Effective in both treatment-naïve and treatment-experienced patients
Integral part of combination antiretroviral therapy (cART)
Dosage & Administration:
The usual adult dose is two tablets taken twice daily with food, or as directed by a healthcare provider. Dosage adjustments may be required based on treatment history and clinical response.
Important Information:
Not a cure for HIV, but essential for long-term management and viral suppression
Regular monitoring of liver function, lipid profile, and viral load is recommended
Use with caution in patients with a history of cardiac conditions or liver impairment
Avoid concomitant use with medications that may cause serious drug interactions
